Skip to main content

For chronic weight management in adult patients with a BMI ≥30 kg/m2, or ≥27 kg/m2 with one or more weight-related comorbidities, as an adjunct to a reduced-calorie diet and increased physical activity. Click for Limitations of Use.

SaxendaCare®: Support for Your Patients

Novo Nordisk offers a comprehensive support program for patients taking Saxenda®

Actor Portrayal.

SaxendaCare®: Support for Your Patients

Novo Nordisk offers a comprehensive support program for patients taking Saxenda®

Live coaches are a phone call away and ready to assist patients with SaxendaCare®

Patients will receive:

SaxendaCare® Welcome Kit graphic
A SaxendaCare® Welcome Kit in the mail, which includes:
  • Welcome letter
  • Health and Wellness guide
  • Portion plate
Certified coaches graphic
Certified coaches
  • Phone calls from Saxenda® coaches who are registered dietitians certified in weight management
  • Patients can also call their live coaches with any questions along their treatment journey
Email program graphic
Email program

Emails guiding patients through the skill-building curriculum

 

A SaxendaCare® Welcome Kit in the mail, which includes:
  • Welcome letter
  • Health and Wellness guide
  • Portion plate
Certified coaches
  • Phone calls from Saxenda® coaches who are registered dietitians certified in weight management
  • Patients can also call their live coaches with any questions along their treatment journey
Email program

Emails guiding patients through the skill-building curriculum

 

Comprehensive Skill-Building Curriculum

Comprehensive Skill-Building Curriculum

SaxendaCare® offers your patients skill-building techniques that can help lead to positive behavior change

SaxendaCare® offers your patients skill-building techniques that can help lead to positive behavior change

Patient image

Actor Portrayal.

Weekly email topics include:

Pen training

  • Pen training
  • Pen training

Dosing schedule

  • Dosing schedule

Reminders about dosing and refills

  • Reminders about dosing and refills

Focusing on short-term goals

  • Focusing on short-term goals

Celebrating the small steps

  • Celebrating the small steps

Finding support

  • Finding support
Patient image

Actor Portrayal.

 

Weekly email topics include:

Making small changes

  • Making small changes

Setting goals and expectations

  • Setting goals and expectations

Identifying motivations

  • Identifying motivations

Finding creative ways to stay on track

  • Finding creative ways to stay on track

Experiencing setbacks

  • Experiencing setbacks

Rewarding yourself for progress made

  • Rewarding yourself for progress made
Patient image

Actor Portrayal.

Weekly email topics include:

Understanding negative self-talk

  • Understanding negative self-talk

Introducing the plate method

  • Introducing the plate method

How to build a healthy, balanced meal, including controlling portions and cutting calories

  • How to build a healthy, balanced meal, including controlling portions and cutting calories

Fiber, fresh fruit, and vegetables, and choosing foods with good fats

  • Fiber, fresh fruit, and vegetables, and choosing foods with good fats
Patient image

Actor Portrayal.

 

Weekly email topics include:

Different kinds of physical activity

  • Different kinds of physical activity

Aerobic exercise, resistance training, flexibility training

  • Aerobic exercise, resistance training, flexibility training

Fitting activity into a regular part of your day

  • Fitting activity into a regular part of your day

Scheduling time for being active, and having a support system

  • Scheduling time for being active, and having a support system

DID YOU KNOW?

DID YOU KNOW?

Patients enrolled in award-winning SaxendaCare® are more adherent to therapy than those who are not enrolled1,a

aBased on a Crossix analysis (December 2016); patients enrolled in SaxendaCare® filled more prescriptions vs those who were not enrolled.

RECOMMENDED CONTENT

Patient Savings

Selected Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Saxenda® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda®.

Indications and Usage

  • Saxenda® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)

Limitations of Use

  • Saxenda® is not indicated for the treatment of type 2 diabetes 
  • Saxenda® and Victoza® both contain the same active ingredient, liraglutide, and therefore should not be used together. Saxenda® should not be used in combination with any other GLP-1 receptor agonist 
  • Saxenda® has not been studied in patients taking insulin. Saxenda® and insulin should not be used together 
  • The safety and efficacy of Saxenda® in combination with other products for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established

Important Safety Information

Contraindications

Saxenda® is contraindicated in:

  • Patients with a personal or family history of MTC or MEN 2 
  • Patients with a prior serious hypersensitivity reaction to liraglutide or to any of the product components 
  • Pregnancy

Warnings and Precautions

  • Risk of Thyroid C-cell Tumors: If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated 
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide postmarketing. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Saxenda® promptly and if pancreatitis is confirmed, do not restart 
  • Acute Gallbladder Disease: Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in patients treated with Saxenda® than with placebo even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated 
  • Risk of Hypoglycemia with Concomitant Use of Anti-Diabetic Therapy: When Saxenda® is used with an insulin secretagogue (eg, a sulfonylurea) serious hypoglycemia can occur. Consider lowering the dose of the insulin secretagogue to reduce the risk of hypoglycemia. Monitor blood glucose parameters prior to starting Saxenda® and during treatment and adjust anti-diabetic drugs as needed 
  • Heart Rate Increase: Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed in patients treated with Saxenda®. Monitor heart rate at regular intervals and inform patients to report palpitations or feelings of a racing heartbeat while at rest during treatment with Saxenda®. Discontinue Saxenda® in patients who experience a sustained increase in resting heart rate 
  • Renal Impairment: Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported, usually in association with nausea, vomiting, diarrhea, or dehydration. Use caution when initiating or escalating doses of Saxenda® in patients with renal impairment 
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (eg, anaphylaxis and angioedema) have been reported in patients treated with liraglutide. If a hypersensitivity reaction occurs, patients should stop taking Saxenda® and promptly seek medical advice 
  • Suicidal Behavior and Ideation: In clinical trials, 9 (0.3%) of 3,384 patients treated with Saxenda® and 2 (0.1%) of the 1,941 treated with placebo reported suicidal ideation; one of the patients treated with Saxenda® attempted suicide. Monitor patients on Saxenda® for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue treatment if patients experience suicidal thoughts or behaviors. Avoid Saxenda® in patients with a history of suicidal attempts or active suicidal ideation

Adverse Events

  • The most common adverse reactions, reported in ≥5% are: nausea, hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase

Drug Interactions

  • Saxenda® causes a delay of gastric emptying, and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda®

Use in Specific Populations

  • There are no data on the presence of liraglutide in human breast milk; liraglutide was present in the milk of lactating rats 
  • Saxenda® has not been studied in patients below 18 years of age and is not recommended for use in pediatric patients 
  • Saxenda® slows gastric emptying. Saxenda® has not been studied in patients with preexisting gastroparesis

Please click here for Prescribing Information, including Boxed Warning.

 

Click below to expand

1. Data on file. Novo Nordisk Inc; Plainsboro, NJ.